New Indications For Sunovion’s Latuda Mean New Marketing Strategy
This article was originally published in The Pink Sheet Daily
The Japanese pharma gained two more indications for the atypical antipsychotic and hopes to differentiate it by stressing its approval as both a monotherapy and adjunctive therapy to standards of care.
You may also be interested in...
While admitting that Sunovion Pharmaceuticals Inc.’s schizophrenia drug Latuda (lurasidone) does not yet have an indication for bipolar I disorder, a sales rep told a psychiatrist it could still be used to treat that condition, FDA’s Office of Prescription Drug Promotion says in a “notice of violation” letter.
TOKYO - Dainippon Sumitomo launched its atypical antipsychotic Latuda (lurasidone) in the U.S. Feb. 4, and now the pressure is on to capitalize on the sales force it acquired in the acquisition of Sepracor. Analysts' eyes will be on Latuda's initial sales to gauge the company's acquired ability to market its in-house drugs in the U.S
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.